New eye drops aim to stop allergy itch and redness

NCT ID NCT07220408

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new eye drop called TL-925 for seasonal allergic conjunctivitis (eye allergies). About 60 adults with a history of eye allergies will receive either the active eye drop or a placebo. Researchers will measure how well it reduces itching and redness after exposure to allergens.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TL-925 eye drops
What this could lead to
If it works, this could provide a new treatment option for eye allergies, reducing itching and redness.
What could go wrong
This is an early Phase 2 study with only 60 people, so results may not apply to everyone. The eye drops may not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGIC CONJUNCTIVITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic conjunctivitis Conjunctivitis, Allergic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Advancing Vision Research

    RECRUITING

    Smyrna, Tennessee, 37167, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.